CHMP recommends eight new drugs for approval – one cancer drug rejected
The expert panel at the EMA recommended eight new drugs for approval at its meeting in June, and backed extensions of therapeutic indication for six existing treatments.
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY CATHERINE BRETT AND NIELSINE NIELSEN
European practitioners will gain new methods for treatment after the June meeting of the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) where the panel recommended several novel drug candidates and new indications for existing drugs.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Leo Pharma receives UK approval for Adtralza
For subscribers
Roche's digital health venture boosted by pandemic
For subscribers
.jpg&w=384&q=75)
